SEC Form 4 · accession 0001172252-26-000002

Aclaris Therapeutics, Inc. · ACRS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Andrew N Schiff

Director

Period of report

Jun 4, 2026

Accepted (ET)

Jun 8, 2026 · 4:15 pm EDT

Rule 10b5-1 plan

box not checked

Issuer CIK

0001557746

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Jun 5, 2026	M	11,580	—	A	25,540	D
Common Stock^F2	holding	—	—		—	434,455	I	By Aisling Capital IV LP

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F4,F3	$4.71	Jun 4, 2026	A	42,350	A	—	Jun 3, 2036	Common Stock	42,350	42,350	D
Restricted Stock Units^F4,F1,F5	—	Jun 4, 2026	A	10,987	A	—	—	Common Stock	10,987	10,987	D
Restricted Stock Units^F1,F6	—	Jun 5, 2026	M	11,580	D	—	—	Common Stock	11,580	0	D

Explanation of responses

F1Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2The reportable securities are owned directly by Aisling Capital IV, LP ("Aisling"), and held indirectly by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling. Dr. Schiff disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.
F3The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan) through each such vesting date.
F4This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy.
F5The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date.
F6The shares underlying these restricted stock units vested on June 5, 2026.